AbGenomics International Status
The company raised $16 million of venture funding from undisclosed investors on October 3, 2014.
Developer of antibody therapeutics designed for the treatment of cancer and immune-related inflammatory diseases. The company's antibody therapeutics focus on the discovery and development of novel therapeutics for unmet medical needs in the field of antibody-drug conjugates (ADC) therapy as well as creates a linker-payload that can be utilized for different targeted tumor indications, providing patients with long term drug-free remission of other immune-mediated diseases.
Generating Revenue
Privately Held (backing)
Venture Capital-Backed
The company raised $16 million of venture funding from undisclosed investors on October 3, 2014.
Most visits will take between 1.5 and 2 hours. The agenda for a specific visit depends on your group, its interests and objectives as well as on the host company. A visit may include a company or industry specific presentation, a discussion around a specific product or service, partnership opportunities, a demo, a meeting of the premises, etc.
Add a review